Dawn Smiley-Byrd is an Endocrinology/Metabolic physician affiliated with Emory University. OpenAlex indexes 66 publications with 5,440 citations (h-index 33).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
48 Hills Creek Rd
Taylorsville, GA 301782051
Telephone
770-684-8700Provider last certified this registry record 19 Apr 2024.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202532 payments$38,297openpaymentsdata.cms.gov ↗
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
- Abbott LaboratoriesProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
60.8%GLP-1 receptor agonist24.9%Ozempic44%Mounjaro40%Trulicity16%Part D≥45 patientsInsulin Analog20.1%Novolog Flexpen18%Humalog Kwikpen U-10014%Lantus Solostar13%Toujeo Max Solostar11%Tresiba Flextouch U-10011%Toujeo Solostar9%Novolog6%Tresiba Flextouch U-2006%Humalog6%Insulin Lispro6%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
25.8%l-Thyroxine19.4%Levothyroxine Sodium53%Synthroid41%Unithroid7%Part D<11 patientsl-Triiodothyronine3.2%Liothyronine Sodium100%Part D≥20 patients+ 1 more class in this area
Cardiovascular
8.3%Statin3.7%Atorvastatin Calcium63%Rosuvastatin Calcium37%Part D<11 patientsACE inhibitor1.3%Lisinopril100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Estimation of Glucose Absorption, Insulin Sensitivity, and Glucose Effectiveness From the Oral Glucose Tolerance Test
The Journal of Clinical Endocrinology & Metabolism
2024 - Impact of obesity on hospital complications and mortality in hospitalized patients with hyperglycemia and diabetes
BMJ Open Diabetes Research & Care
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Keith Delman, MD
Emory University
James Lah, MD
Emory University
John Puskas, MD
Emory University
Craig Hofmeister, MD
Emory University
Jens J. Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Daniel J. Drucker
University of Toronto
Kenneth Cusi, MD
University of Florida College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”